InnoSer News
A day in the life of InnoSer senior research associate Laura Blockken
To provide a range of innovative tools for accelerating drug development, InnoSer brings people from both scientific and business backgrounds together. With our interview series ‘A day in the life of’, let’s take a glimpse into what it is like to be part of this small...
Towards Personalized Medicine By The Early Use Of Patient Data
OPINION Traditional approaches to clinical drug development have created a critical gap between preclinical research and patient applications. Only the drugs that pass big clinical trials reach to the clinic, and a potentially heterogeneous group of patients end up...
Let’s reconsider your research – InnoSer contract breeding services
COVID-19 restrictions brought extra challenges to breeding and maintaining colonies within academic facilities. If you are looking for a service provider resilient to today’s vulnerable environment, InnoSer is here to support you. Let’s put your research back on track...
InnoSer participates in the AACR annual meeting 2020
InnoSer is proud to announce its participation in the annual meeting of the American Association for Cancer Research. As committed contributors to the preclinical oncology field, we look forward to interacting with the community throughout the event. We make this...
A day in the life of InnoSer product manager Tim Rodenburg
To provide a range of innovative tools for accelerating drug development, InnoSer brings people from both scientific and business backgrounds together. With our interview series ‘A day in the life of’, let’s take a glimpse into what it is like to be part of this small...
InnoSer welcomes Pascal Simoëns as its new Business Development Manager
As of June 2020, Pascal Simoëns has joined InnoSer in the role of business development manager (BDM). Pascal will be translating InnoSer's products and services towards the fields of potential and existing client portfolios. By doing so, he will be creating a bridge...
InnoSer joins the Eurostars funded project ‘LEMONAID’
LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...
InnoSer meets you at knowledge for growth event
Organized by flanders.bio since it's establishment in 2004, knowledge for growth brings over 1300 biotech, pharma, medtech, agricultural and chemical industry experts and decision makers, as well as investors, universities, topnotch research institutes, policymakers...
InnoSer welcomes Wim Tiest as its Chief Technology Officer
As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...
Interested In InnoSer’s Services?
Get in touch with us.